Stockwinners Market Radar for February 01, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:36 EST LendingTree CEO buys $705.7K in common stock - In a regulatory filing, LendingTree disclosed that its CEO Douglas Lebda bought 18,268 shares of common stock on January 30th in a total transaction size of $705.7K.

20:08 EST Cathie Wood's ARK Investment bought 109K shares of Invitae today

20:06 EST Biotech Acquisition announces liquidation - Biotech Acquisition "announced that it will not implement the extension of the time period the Company has to complete an initial business combination as approved by its shareholders at an extraordinary general meeting of shareholders held on January 19, 2023 as a result of the investor being unable to deposit the requisite funds into the Company's trust account for the extension. As a result, the Company will dissolve and liquidate in accordance with the provisions of its Amended and Restated Memorandum and Articles of Association, as amended and will redeem all of the outstanding ordinary shares that were included in the units issued in its initial public offering, at a per-share redemption price of approximately $10.15."

18:25 EST Deutsche Bank raises prime lending rate to 7.75% - Deutsche Bank announced that its New York Branch, Deutsche Bank New York, and its affiliate Deutsche Bank Trust Company Americas have increased their prime lending from 7.50% to 7.75% effective tomorrow, February 2, 2023.

18:11 EST Northern Trust raises prime rate to 7.75% from 7.50% - Northern Trust has increased its prime rate from 7.50% to 7.75%, effective Thursday, February 2, 2023.

17:37 EST Webster Financial raises prime lending rate to 7.75% from 7.5%, effective Feb 2

17:32 EST Citizens Bank raises prime lending rate to 7.75% from 7.5% - Citizens Financial announced that Citizens Bank, N.A. has raised its prime lending rate to 7.75% from 7.5%, effective Thursday, February 2, 2023.

17:25 EST TrueBlue sees FY23 CapEx $36M-$40M - Sees FY23 gross margin down 30 to up 30 basis points year-over-year. Sees FY23 SG&A $499M-$505M.

17:20 EST Boeing awarded $1.62B Air Force contract - Boeing was awarded a $1.62B indefinite-delivery/indefinite-quantity contract for guidance subsystem support. This contract provides for Minuteman III Intercontinental Ballistic Missile guidance subsystem support. Work will be performed at Hill AFB, Utah, and is expected to be completed by February 1, 2039. This contract was a sole source acquisition. FY23 operation and maintenance funds in the amount of $8.35M are being obligated at the time of award. The Air Force Nuclear Weapons Center is the contracting activity.

17:03 EST Aris Water Solutions sees Q4 adjusted EBITDA of $36M, below prior guidance - The company states: "Aris Water Solutions announced that its fourth quarter operational results were impacted by customer activity changes and extreme winter weather events experienced during the month of December. Aris's produced water handling volumes continue to grow sequentially, however, customer completion adjustments and unseasonably cold temperatures in the Company's core operating areas during late December reduced operators' production volumes, resulting in total Aris volumes growing less than forecasted. As a result, skim oil revenue was also lower than anticipated for the quarter. Primarily as a consequence of these events and continued inflationary pressure, Adjusted EBITDA for the fourth quarter and full year 2022 is expected to be approximately $36 million and $149 million, respectively, which is below previously provided guidance."

17:01 EST PNC Financial raises prime lending rate to 7.75%, effective February 2

16:48 EST Southwest promotes Lauren Woods to chief information officer - Southwest announced the promotion of Lauren Woods from VP of technology to senior VP and chief information officer, and she will report to chief administration and communications officer Linda Rutherford. Since joining Southwest in 2010, Woods has led initiatives across Southwest's Technology Department, supporting the company's digital and customer channels and various operations teams and platforms. Woods assumes this role following Kathleen Merrill's decision in September 2022 to move to an executive advisor in early 2023.

16:41 EST Comstock Resources added 1.1 Tcfe to its proved reserves in 2022 - Comstock Resources announced that its proved natural gas and oil reserves as of December 31 were estimated at 6.7T cubic feet equivalent or Tcfe, which represents a 9% increase from total proved natural gas and oil reserves of 6.1 Tcfe as of December 31, 2021. The reserve estimates were determined under SEC guidelines and were audited by the Company's independent reserve engineering firm. The 6.7 Tcfe of proved reserves at December 31 were substantially all natural gas, 38% developed and 98% operated by Comstock. The present value, using a 10% discount rate, of the future net cash flows before income taxes of the proved reserves , was approximately $15.5B , using the Company's average first of month 2022 prices of $6.03 per thousand cubic feet of natural gas and $91.21 per barrel of oil. The following table reflects the changes in the proved reserve estimates since the end of 2021:Proved Reserves at December 31, 2021 6,121.8; Proved Reserves at December 31, 2022 6,700.9. Comstock produced 501.1B natural gas equivalent in 2022. In the fourth quarter of 2022, Comstock's production averaged 1,445 million cubic feet of natural gas equivalent per day, which was an increase of 7% over the fourth quarter of 2021. Comstock added 1.1 Tcfe to its proved reserves in 2022 through its Haynesville and Bossier shale drilling activities, which replaced 216% of the Company's 2022 production.

16:38 EST Meritage Homes reports Q4 EPS $7.09, consensus $7.00 - Reports Q4 revenue $1.98B, consensus $1.98B. "As a result of the Meritage team's dedication and exceptional execution, we finished the year strong, delivering 29% more homes and 32% higher home closing revenue in the fourth quarter of 2022 compared to prior year. However, ongoing economic uncertainty continued to impact buyer psychology and undermine housing demand this quarter, generating a 46% decrease in fourth quarter orders," said Steven Hilton, executive chairman of Meritage Homes."

16:32 EST Murphy USA sees FY23 CapEx $375M-$425M - Sees FY23 new stores organic growth up to 45.

16:31 EST Regions Financial increases prime rate to 7.75% - Regions Bank announced it is increasing the Regions prime lending rate to 7.75% from 7.50%, effective Thursday, Feb. 2, 2023.

16:23 EST Alexander & Baldwin CEO Christopher Benjamin to retire, Lance Parker to succeed - Alexander & Baldwin announced that Lance Parker, currently A&B's president & COO, has been appointed the company's new president & CEO effective July 1. Parker will succeed CEO Christopher Benjamin who will retire on June 30 but serve as a consultant through the end of 2023 to ensure a smooth transition and complete various aspects of A&B's simplification strategy. Lance Parker, formerly head of A&B's real estate division, was named COO in 2021 and promoted to president earlier this year.

16:20 EST Timken acquires American Roller Bearing Company, terms not disclosed - The Timken Company has acquired the assets of American Roller Bearing Company, a North Carolina-based manufacturer of industrial bearings. ARB's offerings join Timken's industry-leading portfolio of engineered bearing solutions. ARB, which boasts a large U.S. installed base and strong aftermarket business, generated sales of more than $30M in 2022. Timken funded the transaction with cash on hand.

16:18 EST Curtiss-Wright awarded contract for new Enduring Shield platform from Dynetics - Curtiss-Wright (CW) announced that it has been awarded a contract to support the new Enduring Shield platform from Dynetics, a Leidos company (LDOS), to meet the U.S. Army's cruise missile defense needs. Under the contract, Curtiss-Wright will design and build electromechanical actuators for the first 16 Dynetics launcher platforms, with an option for 400 additional launchers with associated interceptors. The U.S. Army Program Executive Office Missiles and Space awarded Dynetics the contract for the Indirect Fires Protection Capability program to produce its mobile ground-based weapon system. The system is designed to acquire, track, engage and defeat cruise missiles, rockets and unmanned aircraft system threats.

16:16 EST VICI Properties provides construction loan of up $287.9M to Great Wolf Resorts - VICI Properties announced that the Company has agreed to provide a construction loan for up to $287.9 million to Great Wolf Resorts related to the development of Great Wolf Lodge in Mashantucket, Connecticut, a family resort project adjacent to the Foxwoods Resort Casino. The 549-room indoor water park resort was officially announced today during a groundbreaking event and is expected to start welcoming guests by mid-2025. This transaction represents VICI Properties' fourth loan investment with Great Wolf for a total capital commitment of $553.4 million as part of the Company's previously announced strategic arrangement to provide financing to support the funding of the development of Great Wolf's pipeline.

16:14 EST Meta Platforms announces $40B increase in share repurchase authorization - Meta stated: "We repurchased $6.91B and $27.93B of our Class A common stock in the fourth quarter and full year 2022, respectively. As of December 31, 2022, we had $10.87B available and authorized for repurchases. We also announced today a $40B increase in our share repurchase authorization."

16:11 EST AEye names Matt Fisch as CEO - AEye (LIDR) "announced it has named Matt Fisch as the company's new CEO and as a member of its board of directors effective February 13, 2023. Fisch is a deeply technical C-level leader with 30 years of experience delivering breakout products across industries, and scaling software organizations at multi-billion-dollar global companies including HARMAN International, Intel, and Verifone. He takes the reins at AEye as the company transitions into commercialization of its award-winning product line across multiple markets. Most recently, he held SVP and CTO positions at Gentherm (THRM), a $1.1B developer of thermal management technologies which has been named a Supplier of the Year by General Motors two years in a row. There, he led the company's transformation to align with the electrification of the automotive industry and the shifting value proposition to software and systems."

16:10 EST Avista files multiyear electric and natural gas rate plan in Idaho - Avista has filed a multiyear rate plan with the Idaho Public Utilities Commission that would allow the Company to recover costs for fixed expenses and ongoing investments to infrastructure, technology and more. If approved, new rates would be effective in Sept. 2023 and Sept. 2024."As an energy provider, we understand we play a vital role in the daily lives of those we serve, and we take this responsibility seriously," said Avista president and CEO Dennis Vermillion. "As costs for goods and services have gone up across the board, we recognize how challenging increases in energy prices can be for our customers. We work hard to make decisions that will help keep these costs affordable, because we know this matters to all of our customers." "Part of the responsibility of providing an essential service is to make sure customers have energy when they need it. This means that we must continue to make important and necessary investments to the infrastructure that serves our customers such as replacing wood distribution poles and aging natural gas pipelines, making our system more resilient to the threat of wildfires and storms, upgrading customer-facing technology and substations, and much more. We've made these investments on behalf of our customers because it's the right thing to do.

16:10 EST Meta Platforms reports FoA and RL segment restructuring charges - Meta said: "During the quarter ended December 31, 2022, we took several measures to pursue greater efficiency and to realign our business and strategic priorities. This includes a facilities consolidation strategy to sublease, early terminate, or abandon several office buildings under operating leases, a layoff of approximately 11,000 of our employees across the FoA and RL segments, and a pivot towards a next generation data center design, including cancellation of multiple data center projects. Total restructuring charges recorded under our FoA segment were $3.76 billion and RL segment were $440 million during the fourth quarter of 2022. Excluding these charges, our operating margin would have been 13 percentage points higher, our effective tax rate would have been one percentage point lower, and our diluted EPS would have been $1.24 higher for the fourth quarter of 2022. The impact of the severance and other personnel costs recorded in the fourth quarter of 2022 was not material after offsetting with the savings from the decreases in payroll, bonus and other benefits expenses."

16:09 EST Hawkins increases quarterly cash dividend by 7% to 15c per share - The Board of Directors of Hawkins at its meeting on February 1 increased its quarterly cash dividend 7% to 15c per share payable March 3 , to shareholders of record at the close of business on February 17. Hawkins has consistently paid out a dividend since 1985.

16:09 EST Meta Platforms up 13% in after-hours trading following Q4 report - Meta shares are up $20.04, or 13%, to $173.16 in after-hours trading.

16:08 EST Meta reports Facebook MAUs of 2.96B as of Dec. 31, up 2% year-over-year - Meta Platforms reports family daily active people, or DAP, was 2.96B on average for December 2022, an increase of 5% year-over-year. Family monthly active people, or MAP, was 3.74B as of December 31, 2022, an increase of 4% year-over-year.

16:07 EST Meta reports Facebook DAUs 2B on average for December, up 4% year-over-year

16:01 EST CSG raises quarterly dividend 6% to 28c per share - The new dividend is payable on March 30, 2023 for shareholders of record as of the close of business on March 17, 2023.

15:36 EST Cemtrex trading resumes

15:31 EST Cemtrex trading halted, volatility trading pause

15:02 EST Allogene Therapeutics presents preclinical Dagger platform technology data - Allogene Therapeutics presented preclinical data highlighting the company's next generation Dagger platform technology at the Emerging Cellular Therapies at the Forefront of Cancer Immunotherapy Keystone Symposia in Banff, Alberta, Canada. The Dagger technology, first unveiled at the company's R&D Showcase in November 2022, is designed to resist rejection of AlloCAR T cells by the host immune cells, enabling a prolonged window of persistence during which AlloCAR T cells can expand and actively target and destroy cancer cells. Dagger is a component of Allogene's anti-CD70 product candidate ALLO-316, which is being evaluated in TRAVERSE, a Phase 1 study of patients with relapsed/refractory renal cell carcinoma, or RCC. The Dagger platform arms AlloCAR T cells with a CD70-targeting receptor designed to recognize and deplete CD70 positive host cells while also masking the CD70 molecule expressed on the AlloCAR T cells themselves, preventing fratricide. CD70 is expressed on activated T cells and NK cells, and by selectively depleting alloreactive host cells, Dagger can potentially prevent the immune rejection of AlloCAR T cells. The results from these pre-clinical studies show that: A CD70 Dagger construct was optimized to selectively eliminate alloreactive T cells, enabling enhanced AlloCAR T cell survival in several in vitro models of rejection. Allogeneic CAR T cells expressing dual CD19 CAR and CD70 Dagger receptors demonstrated the ability to simultaneously kill CD19-positive tumor cells and resist rejection and fratricide. CD19 AlloCAR T cells armed with a CD70 Dagger were endowed with dual specificity and prevented CD19 antigen loss dependent escape by tumor cells in vitro and in vivo. The company has pursued an integrated strategy within Research and Development aimed at matching technology with insights obtained from the clinic to improve patient outcomes. In addition to ALLO-316, the company plans to deploy Dagger technology to enhance the persistence and activity of next generation AlloCAR T products.

14:39 EST Truist Financial increases prime rate to 7.75% - Truist Financial announced an increase in its prime lending rate to 7.75% from 7.50%, effective tomorrow, Feb. 2.

14:07 EST Fifth Third to increase prime lending rate to 7.75% - Fifth Third Bank, National Association, announced it will increase its prime lending rate to 7.75%, effective immediately.

13:27 EST Honda reports January U.S. sales up 14.3% to 84,514 units - American Honda reports sales up 14.3% year-over-year to 84,514 units last month as "stronger inventory improves January sales start." Reference Link

13:16 EST FDA revises EUA for Paxlovid to remove SARS-CoV-2 viral testing requirement - The FDA issued a fact sheet for healthcare providers on the Emergency Use Authorization for Pfizer's Paxlovid, which indicates that the EUA has been revised to remove a previous requirement of SARS-CoV-2 viral testing. Reference Link

13:00 EST Kroger delivery expands to South Florida - Kroger announced the opening of a new spoke facility in South Florida. Joined by the local community, Kroger celebrated the expansion of the delivery service and welcomed 90 new associates. This facility opening means customers can access Kroger's incredible selection of fresh items, unique Our Brands products and favorite national brands, as well as individualized offers for the groceries most important to their families - all delivered directly to their door by a friendly, professional Kroger associate. "We are thrilled to connect more Floridians to the Kroger Delivery shopping experience, which brings thousands of digital coupons, valuable fuel points* and the freshest products directly to customers' doors," said Bill Bennett, Kroger Vice President, and Head of E-commerce. "Whether they are using the Kroger app or browsing our weekly ad at Kroger.com, customers can enjoy fresh, high-quality, affordable groceries delivered by best-in-class uniformed drivers."

12:14 EST Nestle Canada announces wind down, exit of Frozen Meals & Pizza business - Nestle Canada announced the wind down and exit of its Frozen Meals & Pizza business over the next six months in Canada. This decision is driven by the company's strategy to focus on categories that support long-term business growth and allow for reinvestment in portfolio lines. This includes Confectionery, Coffee and Beverages, Ice Cream, Infant Foods and Supplements, Health Science products, Foodservice, Premium Waters and Pet Food. The following product lines that will be affected are as follows: Delissio; Stouffer's; Lean Cuisine; Life Cuisine. Nestle Canada does not have a factory in Canada that manufactures any of its Frozen Meals or Pizza products. The company will work with its retail partners to facilitate the exit of the affected products.

12:00 EST WestRock falls -13.0% - WestRock is down -13.0%, or -$5.11 to $34.13.

12:00 EST Lanvin Group falls -14.0% - Lanvin Group is down -14.0%, or -$1.10 to $6.75.

12:00 EST Dynatrace rises 11.2% - Dynatrace is up 11.2%, or $4.29 to $42.73.

11:52 EST Airbus announces 'amicable settlement' in legal dispute with Qatar Airways - Airbus stated: "Qatar Airways and Airbus are pleased to have reached an amicable and mutually agreeable settlement in relation to their legal dispute over A350 surface degradation and the grounding of A350 aircraft. A repair project is now underway and both parties look forward to getting these aircraft safely back in the air. The details of the settlement are confidential and the parties will now proceed to discontinue their legal claims. The settlement agreement is not an admission of liability for either party. This agreement will enable Qatar Airways and Airbus to move forward and work together as partners." Reference Link

11:39 EST Qualtrics up 5% after Silver Lake says intends to submit bid - Shares of Qualtrics (XM) are up 75c, or 5%, to $16.52 after Silver Lake, which holds a 14.9% stake in the company, said in a regulatory filing earlier that it intends to submit a proposal that could result in the firm and/or their affiliates acquiring all or substantially all of the outstanding capital stock of the company. The filing, which noted that Silver Lake Partners VI DE, L.P. and Silver Lake Technology Investors VI, L.P. purchased 676,938 shares of Class A Common Stock for investment purposes for an aggregate purchase price of approximately $18.8M from February 23 through March 11, 2022, also stated: "On January 26, 2023, SAP SE, the controlling stockholder of the Issuer, announced that it intends to explore a sale of its stake in the Issuer (the "SAP Proposal"). In connection with the announcement of the SAP Proposal, on January 31, 2023, Silver Lake Management Company V, L.L.C. entered into an amendment and restatement of its pre-existing customary mutual non-disclosure agreement with the Issuer. Pursuant to the terms of the Non-disclosure Agreement, as amended, SLMC V has agreed that for a period of one year, among other things and subject to certain exceptions, SLMC V and its affiliated investment funds, which includes the Reporting Persons, will not: acquire any voting securities of the Issuer; or participate in any solicitation of proxies to vote securities of the Issuer... In connection with the announcement of the SAP Proposal, the Reporting Persons have discussed and explored, and expect to continue to discuss and explore, various potential alternatives with respect to their investment in the Issuer... The Reporting Persons currently intend to submit a proposal, which could also lead to one or more subsequent revised or different proposals, that could result in the Reporting Persons and/or their affiliates acquiring all or substantially all of the outstanding capital stock of the Issuer, which would result in a de-listing and de-registration of the Class A Common Stock ."

11:17 EST Mercury Systems initiates review of strategic alternatives - Last night, along with its report of operating results for the second quarter of fiscal 2023, Mercury Systems reported that its board has decided to initiate a review of strategic alternatives. The company stated: "The Mercury board of directors regularly reviews the company's strategic plan, priorities and opportunities as part of its commitment to act in the best interest of the company and its shareholders. To that end, the board has decided to initiate a review of strategic alternatives to enhance shareholder value. There can be no assurance that any transaction will be approved or consummated. The company does not intend to disclose developments relating to this process unless and until the board has approved a specific agreement or transaction or has terminated its review. Citi and Goldman Sachs & Co. LLC are serving as financial advisors to Mercury, and Shearman & Sterling LLP is serving as legal counsel."

11:01 EST Trimble announces Trimble Maps integration for OneRail delivery platform - Trimble and OneRail announced the integration of Trimble Maps technology as part of OneRail's delivery platform to enhance last mile logistics.

10:35 EST Credit card stocks down after CFPB proposes changes to late fee rules

10:31 EST United Insurance sells Florida personal lines renewal rights to Slide Insurance - United Insurance Holdings sold the renewal rights to UPC Insurance's personal lines business in the state of Florida, and sold certain data and intellectual property to Slide Insurance. The transaction accelerates the run-off of UPC Insurance's personal lines portfolio, further reducing its exposure to Florida liabilities and allowing UPC Insurance to focus on its fast-growing commercial specialty property portfolio, underwritten by American Coastal Insurance Company. Under the terms of the transaction, UPC Insurance will cancel approximately 72,000 Florida personal lines policies on February 1, 2023, and Slide will immediately issue replacement policies. Additionally, Slide will make offers of coverage to additional Florida personal lines policies expiring in April 2023. UPC Insurance retains all liabilities with respect to claims with a date of loss on or prior to January 31, 2023. UPC Insurance and Slide also entered into an Asset Purchase and Services Agreement effective February 1, 2023, whereby UPC Insurance sold certain intellectual property and data to Slide and UPC Insurance will provide Slide with policy administration services in exchange for two percent of gross earned premium of the policies subject to the Renewal Rights Agreement plus costs incurred by UPC Insurance to provide services.

10:19 EST Cyren says existing, projected cash not sufficient to meet capital needs - In the absence of additional sources of liquidity, management anticipates that the Company's existing cash and projected cash flows from operations will not be sufficient to meet the Company's working capital needs in the near term. The Company continues to assess all of its strategic options, including potential asset monetization or liquidation. In the event that the Company determines that its liquidity will not allow it to meet its obligations as they become due or that additional sources of liquidity will not be available, the Company may need to pursue options available under applicable insolvency laws, including winding up its operations.

10:16 EST Smart for Life granted extension to regain Nasdaq compliance - Smart for Life announced that the Company received a notification letter from The Nasdaq Stock Market on January 25, 2023, notifying the Company that the Nasdaq Hearings Panel has granted an exception from two continued listing standards, Nasdaq's stockholders' equity requirement of $2,500,000, as set forth in Listing Rule 5550(b), and Nasdaq's $1.00 bid price requirement, as set forth in Listing Rule 5550(a)(2), until May 30, 2023. As previously disclosed, on December 5, 2022, the Company requested a hearing with the Panel, which was held on January 19, 2023. As a result of the Panel's decision, the Company now has until May 30, 2023 to regain compliance with the Equity Rule and the Bid Price Rule. This news was preceded by the Company's successful conversion of approximately $2.5 million of debt to equity and the Company's announcement of its upcoming Annual Shareholder meeting scheduled for March 15, 2023.

10:00 EST Snap falls -13.8% - Snap is down -13.8%, or -$1.59 to $9.97.

10:00 EST Bread Financial falls -14.2% - Bread Financial is down -14.2%, or -$5.83 to $35.20.

10:00 EST Huya rises 12.2% - Huya is up 12.2%, or 67c to $6.17.

09:58 EST Match Group expects to reduce global workforce by 8% in aggregate - The company said on its Q4 earnings conference call that it has already reduced roles in the U.S., and the process is "ongoing" in other countries. Match expects to incur $6M of severance and similar costs related to cost savings in 2023.

09:51 EST Jaguar Health, SynWorld mutually agree to terminate license agreement - Jaguar Health and SynWorld Technologies announced that the two companies have mutually agreed to terminate the exclusive license and services agreement executed in June 2022 for the treatment of diarrhea in dogs in the China market with Jaguar's Canalevia prescription drug product effective January 31, 2023. On the effective date of termination of the Canalevia Agreement, all licenses granted to SynWorld by Jaguar under the Canalevia Agreement were revoked and the rights granted thereunder reverted back to Jaguar.

09:49 EST Pressure BioSciences receives $600,000 order for 16 PCT instruments - Pressure BioSciences announced entrance into an exclusive distribution agreement for the People's Republic of China with PRS International Trade. PRS International prepaid for the entire purchase of 16 Barocycler EXT units for a total of nearly $600,000, with a commitment to purchase additional units and related consumables before the end of 2023. This historic purchase of PBIO's original high-pressure technology instruments comes on the back of a surge in purchase orders for all product categories of the Company's pressure-based instruments and consumables.

09:47 EST Snap falls -12.2% - Snap is down -12.2%, or -$1.41 to $10.15.

09:47 EST WestRock falls -13.8% - WestRock is down -13.8%, or -$5.42 to $33.82.

09:47 EST Huya rises 11.1% - Huya is up 11.1%, or 61c to $6.11.

09:43 EST ZoomInfo appoints Ali Dasdan as CTO, Dave Justice as chief revenue officer - ZoomInfo (ZI) announced the appointments of Ali Dasdan as CTO and Dave Justice as chief revenue officer. Dasdan, whose appointment is effective immediately, joins ZoomInfo from Atlassian (TEAM) where he was the head of engineering for work management and led a suite of team productivity tools, including Confluence, Trello, and Jira Work Management. Dasdan will oversee the company's innovation and development efforts, including leading the product-led growth organization focused on bringing the power of the ZoomInfo platform to more users. Nir Keren, ZoomInfo's CTO since 2015, will be leaving the organization. Justice, who will join ZoomInfo on February 6, served as chief revenue officer of PagerDuty (PD) for the past three years, where he helped architect a land-and-expand motion that scaled the IT SaaS platform's enterprise business significantly.

09:38 EST Lionheart III Corp trading halted, volatility trading pause

09:31 EST Motorsport Games Inc trading halted, volatility trading pause

09:30 EST Infrastructure Investments Fund completes South Jersey Industries acquisition - South Jersey Industries announced that IIF's acquisition of SJI is closing today. SJI also announced that its Board of Directors today declared a "stub period" dividend in an amount equal to $0.1499 per share of SJI common stock. The dividend amount reflects the most recent regular quarterly SJI common stock dividend rate of $0.3100 per share prorated for the 44 days from and including December 20, 2022, the day after the record date for the most recent regular quarterly SJI common stock dividend, and today. SJI's last trading day on the NYSE was January 31, 2023. The "stub period" dividend is payable to the holders of record of SJI common stock as of the close of business on January 31, 2023 and is payable today, February 1, 2023. Shareholders as of today will also be entitled to receive merger consideration of $36.00 per share in cash.

09:27 EST Motorsport Games announces $3.9M registered direct offering - Motorsport Games has entered into a definitive agreement for the issuance and sale of an aggregate of 183,020 shares of the Company's Class A common stock at a purchase price of $21.40 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about February 3, 2023, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to Motorsport Games from the offering are expected to be approximately $3.9M, before deducting the placement agent's fees and other offering expenses payable by the Company. Motorsport Games currently intends to use the net proceeds from the private placement for development of multiple games, working capital and general corporate purposes.

09:25 EST Blue Water announces partnership with AbVacc for joint development of vaccines - Blue Water Vaccines announced a collaboration with AbVacc for the joint development of vaccine candidates targeting monkeypox and Marburg virus disease. Both candidate vaccines will utilize BWV's norovirus shell and protrusion virus-like particle platform, which allows for the presentation of multiple antigens on the surface of either the S or P particle of a norovirus backbone. BWV previously announced plans to explore a novel monkeypox vaccine candidate using this platform and under this agreement, AbVacc & BWV plan to work collaboratively to optimize the vaccine design and conduct preclinical immunogenicity and efficacy studies. In addition to monkeypox vaccine development, AbVacc will utilize its extensive expertise in MVD to develop a novel vaccine targeting Marburg virus using BWV's VLP platform. "As various epidemics continue to emerge around the world, there has never been a better time to invest in the creation of preventative vaccines," said Joseph Hernandez, Chairman and Chief Executive Officer of Blue Water Vaccines. "We strongly believe in the versatility of this platform and are honored to partner with the esteemed research team at AbVacc to push these candidates forward toward clinical development."

09:23 EST OceanPal announces entry into agreement to acquire Panamax dry bulk vessel - OceanPal (OP) announced that it has signed, through a separate wholly-owned subsidiary, a Memorandum of Agreement dated February 1, 2023, to acquire the m/v Melia from Diana Shipping (DSX), a related party of the Company, for an aggregate purchase price of $14.0M. Of the purchase price, $4.0M was paid in cash upon the signing of the Memorandum of Agreement and the remaining amount is expected to be paid upon delivery of the vessel to OceanPal Inc. in the form of shares of the Company's Series D Preferred Stock, the terms of which are set forth in the statement of designation of the Series D Preferred Stock. The m/v Melia is a 2005-built Panamax dry bulk vessel with a carrying capacity of 76,225 dwt. The Company expects to take delivery of the vessel by the end of February 2023. Upon completion of the aforementioned purchase, OceanPal Inc.'s fleet will consist of 5 dry bulk vessels.

09:21 EST Qualigen Therapeutics provides letter to shareholders - Qualigen Therapeutics issued the following letter to its stockholders: "I am excited to update you on our significant accomplishments for 2022 and to review our priorities for the coming months. The year 2022 was one in which we faced significant macro-environmental headwinds, including supply chain shortages and higher interest rates affecting our industry.... In advancing our cancer therapeutics pipeline, our activities centered around our lead program, QN-302... At the end of December 2022, upon our request, we received Pre-IND feedback from the U.S. Food and Drug Administration. This feedback has been instructive in our activities to help us prepare our Investigational New Drug submission, which we remain on track to file with the FDA in the first half of 2023. Following clearance of the IND submission, we intend to initiate a Phase 1 clinical trial, for which we look forward to providing more detailed information at the appropriate time. In the meantime, we are very pleased that QN-302 was granted Orphan Drug Designation for the treatment of pancreatic cancer by the FDA just a couple of weeks ago... we are focused on executing on our strategy to secure non-dilutive funding for various QN-302 development efforts. Upon execution of a potential agreement at a future time, we would ensure all derivative intellectual property be exclusively owned by Qualigen Therapeutics. Expanded RAS discovery efforts to target KRAS G12D and G12C. In parallel with our QN-302 development, we continue to advance the efforts in our RAS therapeutic platform, with the goal of identifying a lead compound to enter IND-enabling studies. As part of these activities, we have been actively submitting data to scientific conferences for presentation and publication. Last May, two of our abstracts were featured in the American Society for Clinical Oncology's (ASCO) Annual Meeting Abstract Book. Recently, in October 2022, our collaborator presented two posters on efficacy in two cancer types at the National Cancer Institute's 4th Annual RAS Symposium, a gathering of worldwide RAS experts. Invitations to present data at these key scientific venues provided validation that our development approach has merit within the oncology research community. Development partners sought for QN-247 program... Qualigen believes the encouraging efficacy and safety results in TNBC animal model warrant further investigation. As a result, we are seeking partners to help advance this program into IND-enabling studies, as we focus our therapeutics resources on the development of QN-302 and our RAS platform. NanoSynex Progressing Antimicrobial Susceptibility Testing platform. Leveraging our diagnostics know-how, in May 2022, we announced our majority investment in private Israeli diagnostics developer NanoSynex, which is developing an Antimicrobial Susceptibility Testing platform that aims to provide clinical laboratories with a rapid, accurate and personalized test for bacterial infections, with the goal of quickly matching the correct antibiotics to treat a patient's particular infection... NanoSynex's AST platform is designed to enable better targeting of antibiotics for their most suitable uses to ultimately result in faster and more efficacious treatment, hence reducing hospital mortality and morbidity rates."

09:17 EST Euronet's platform to enhance prepaid card issuing services for SOLFIN - Euronet announced an agreement with LATAM digital wallet provider Paga Aqui Servicios SOLFIN where Euronet's Ren Payments Platform will provide complete issuing services for a minimum of 250,000 prepaid cards and up to 10 million cards over the next 10 years. The partnership, one of the largest prepaid card programs in Central America, also will enable SOLFIN to expand its footprint beyond Costa Rica and Guatemala to other Central American countries in the future. For this project, Euronet is hosting Ren in one of its global data centers and providing the SOLFIN wallet access to Ren's issuing capabilities through customizable APIs. The SaaS-based approach enables SOLFIN to focus on its new wallet enhancements while Euronet maintains the core Ren functionality for them. "We are excited to be working with SOLFIN," said Oscar Munoz, Head of Sales for Ren Americas. "They have a strong presence in the region and are committed to delivering prepaid card services that meet the needs of their customers."

09:17 EST Illumina appoints Joydeep Goswami as CFO - Illumina announced Joydeep Goswami has been appointed CFO, effective immediately. Goswami previously served as Illumina's Chief Strategy and Corporate Development Officer and interim CFO. As CFO, Goswami will be responsible for the Company's financial planning and analysis, accounting, investor relations, internal audit, tax, and treasury functions. He will also continue to lead the corporate development and strategic planning function. Goswami assumed all CFO responsibilities on an interim basis in July 2022 and has served as Chief Strategy and Corporate Development Officer since 2019. With more than 20 years of experience in the life sciences industry, Goswami has held various senior and international management roles with P&L responsibility. Prior to joining Illumina, he was President, Clinical Next Generation Sequencing (NGS) and Oncology at Thermo Fisher Scientific, where he led the expanded application of NGS across clinical oncology, research, and reproductive health segments. While at Thermo Fisher, he also served as President, Asia Pacific and Japan leading the integration of Life Technologies APJ business into the regional Thermo Fisher organization, doubling organic growth while significantly improving the profitability of the business. Earlier in his career, Goswami was President, Japan at Life Technologies where he drove strong top and bottom-line growth through key customer engagement. Goswami began his career at McKinsey & Company, where he managed projects and teams serving global clients spanning several industries including pharmaceuticals, medical products, chemical, private equity and technology.

09:16 EST Amplitude announces Kristina Johnson as Chief Human Resources Officer - Amplitude announced the appointment of Kristina "KJ" Johnson as Chief Human Resources Officer. With a track record for building people-first cultures at fast-growing organizations, Johnson will lead Amplitude's People and Workplace function-including talent acquisition and development, diversity, equity & inclusion, DE&I , total rewards, employee engagement, and more. She will also join Amplitude's executive leadership team and report to Spenser Skates, Co-founder and CEO of Amplitude. "The People function is incredibly important to building a great organization, and KJ has the experience and leadership we need to be successful in our next phase of growth," said Skates. "KJ innately lives our cultural values, has seen the level of scale we're growing to, and has a strong perspective on how to build high-performing teams. KJ is a phenomenal leader, and I'm excited to work alongside her."

09:14 EST Brilliant Earth opens 26th showroom in Charlotte, North Carolina - Brilliant Earth announced the opening of its 26th showroom in Charlotte, North Carolina. "We are excited to announce the opening of our showroom in Charlotte just in time for Valentine's Day gifting and proposal season," said Kathryn Money, SVP of Merchandising and Retail Expansion. "The continued expansion of our brick and mortar presence brings our seamless personalized omnichannel experience to more and more customers across the United States."

09:13 EST LPL Financial closes acquisition of Boenning & Scattergood - LPL Financial announced the closing of its acquisition of the Private Client Group business of Boenning & Scattergood, a broker/dealer and registered investment adviser headquartered in West Conshohocken, Pa. The 108-year-old business will operate under LPL's Linsco employee advisor affiliation model, which allows the firm to retain its brand and operations, while benefitting from LPL's integrated advisory and brokerage platform. As a result of the transaction, approximately $4 billion of client assets are expected to onboard to LPL's custodial platform.

09:11 EST Mayfair Gold reports metallurgical test results for Fenn-Gib Deposit - Mayfair Gold announced results from the Company's 2022-23 advanced metallurgical test program performed on a core-based bulk sample from the Fenn-Gib deposit. Metallurgical testing was conducted at SGS-Lakefield under the supervision of Mr. Steve Haggarty, P. Eng., metallurgical consultant to Mayfair Gold. The 100% controlled Fenn-Gib deposit, located in the Timmins region of Northeast Ontario, hosts an NI 43-101 pit-constrained Indicated Resource of 3.06M gold ounces (see the "About Mayfair" section below) with disseminated gold mineralization striking east-west on the Pipestone Fault over more than 1.25 kilometers and is up to 300 meters wide at the west end. Preliminary metallurgical tests conducted in 2021-22, based on a feed grind size of P80 75 microns, returned whole-ore cyanidation gold recoveries of 84.3% and gold flotation recoveries to a final concentrate approaching 94%. In late 2022, SGS conducted flotation rate kinetic tests at varying grind sizes to flotation and, in early 2023, undertook concentrate cyanidation tests at varying concentrate regrind sizes to optimize overall gold recovery from a flotation-cyanidation flowsheet alternative. Recent test results confirm that there is a negligible difference in gold recovery when coarsening the grind size to flotation from P80 75 microm to P80 106 microm. Sulfide flotation to a rougher concentrate achieved 96% Au recovery with a target 20-25% mass pull. In addition, fine grinding of rougher concentrate at P80 10 microm followed by cyanidation yielded 95.0% Au extraction from the reground rougher concentrate, resulting in an overall 91.2% Au recovery from Flotation-Regrinding-Cyanidation. Metallurgical testing completed to date is sufficient to advance conceptual engineering as a pre-feasibility study, which is planned to commence shortly. Processing concepts presently being studied include pyrite flotation to produce a gold-bearing final concentrate for offsite treatment, and pyrite flotation-regrinding-cyanidation for onsite gold recovery. Finally, approximately 112,000m of the planned 140,000m Fenn-Gib infill and expansion resource drill program has been completed to date. Based on assay results from 110,000m of drilling, a further resource update is planned in Q2 2023.

09:08 EST Micron appoints Raj Narasimhan as SVP, GM of Compute, Networking business unit - Micron Technology announced the appointment of Raj Narasimhan to the role of senior vice president and general manager of its Compute and Networking Business Unit. Narasimhan will be responsible for leading Micron's largest business, driving advances in memory products focused on high-performance computing, artificial intelligence, and cloud and client computing. He will report to Sumit Sadana, Micron's executive vice president and chief business officer. Narasimhan began his career at Micron in 1995 in R&D, before taking on a variety of operational roles, including as the site director of Micron's Manassas, Virginia, fab. He also held global assignments in Singapore and Japan. Most recently, Narasimhan was Micron's corporate vice president of Global Quality. Narasimhan succeeds Raj Hazra.

09:07 EST Taboola announces experiments with integrating AI into ad platform - Taboola announced it is experimenting with integrating generative AI, including ChatGPT by OpenAI, into its ad platform. One application of the new technology enables advertisers to use AI to generate optimized ads, titles and content, to take their advertising campaigns to the next level. With this application, advertisers will be able to quickly generate multiple ad variations using natural language processing and machine learning, allowing them to choose creative content based on their queries with the ultimate goal of increasing the efficiency and effectiveness of their campaigns. "We are thrilled to be experimenting with ways we can integrate cutting-edge generative AI technology into our platform, including the highly advanced ChatGPT," said Adam Singolda, Founder & CEO of Taboola. "We believe AI technologies will revolutionize the way advertisers create and optimize their ads to drive performance, providing them with additional tools they need to succeed in the fast-paced world of online advertising."

09:06 EST Gentex to open production facility in Grand Rapids - Gentex Corporation announced that it plans to open a satellite production facility that will bring 50 new jobs to the Madison Square neighborhood of Grand Rapids. By expanding its manufacturing footprint, the company hopes to boost its employee base and provide greater access to well-paying jobs as it continues to implement meaningful solutions to address the ongoing labor shortage. "Rising transportation costs make commuting increasingly difficult, so if Gentex wants to recruit employees from Grand Rapids, we need to be here," said Gentex President and CEO Steve Downing. "And by locating a satellite plant and creating jobs in a neighborhood near city center, our goal is to strengthen not only Gentex, but also the surrounding community, and we look forward to future opportunities to do so." The decision to locate in the Madison Square neighborhood came after months of working alongside Amplify GR, a local non-profit that works in partnership to bring together neighbors, businesses, and local organizations to help strengthen neighborhoods.

09:05 EST Iveda Solutions brings $1M in smart city technology to Taiwan - Iveda announced $1M in new technology deals with organizations and municipalities across Taiwan. Through contracts with the Taiwan Stock Exchange, Tainan Solar Park, Taipei City Government Public Works Bureau, and additional Taiwanese government entities, Iveda technology will be implemented over the next several months in an effort to upgrade and improve upon network communication systems, effectively increasing video surveillance capacity while enhancing national safety and security. "As an organization on the forefront of digital transformation, we're seeing cities and countries across the globe - especially those with dense populations - investing in smarter infrastructure to maintain and manage operational efficiencies through accurate, real-time data," said David Ly, Iveda Founder and CEO. "Iveda is thrilled to be a part of Taiwan's continued journey toward smart city status. Through these additional contracts, we are effectively equipping local organizations and municipalities with the technology needed to prepare their communication networks and safety systems, all while enabling personnel to automate wherever possible, limiting waste in both energy and human power for true smart city innovation."

09:04 EST Nano Dimension receives purchase order from U.S. government defense supplier - Nano Dimension announced that it has received a purchase order from a supplier to the U.S. government defense industry, for a DragonFly IV, the leading Additive Manufacturing Electronics, AME, 3D-printer. The customer is a supplier to the U.S. government defense community, in particular the intelligence ecosystem, enabling innovation for the next generation battlespace. It leverages solutions designed to support the rapidly evolving technological environment. This customer, like many others, sees the DragonFly IV as a critical means to advance innovation in a way that other technologies of electronics manufacturing cannot achieve. Yoav Stern, Chairman and Chief Executive Officer of Nano Dimension, stated: "Many of us, almost all of Nano Dimension's management and a majority of our employees, have had prolonged and intense periods of our lives serving our countries in the defense forces, be it Air Force, Special Forces, Government Intelligence Agencies and others. As such, we are proud to be able to supply a unique group like this customer with technologies that will help fulfil national missions while hopefully reducing risks and saving people's lives. It is an honor for us to be a business partner of such people, missions, and efforts."

09:03 EST Canoo awarded contract by The Defense Innovation Unit - The Defense Innovation Unit awarded Canoo a contract to supply battery modules for analysis and demonstration. This award supports the U.S. Department of Defense focus to incorporate scalable and adaptable capabilities in tactical environments. Canoo's proprietary battery system is modular to support different vehicle configurations and engineered to provide industry leading energy density. The system is designed to be flexible and compatible with cells from leading battery providers and engineered to evolve with changes in cell size and chemistry as the industry matures, scales and reduces costs. This contract follows Canoo's delivery of a Light Tactical Vehicle to the U.S. Army in November, and its selection to provide NASA with crew transportation vehicles to support the Artemis lunar landing missions

09:02 EST Rackspace Technology appoints Roberts to board of directors - Rackspace Technology (RKT) announced the appointment of Anthony Roberts to its board of directors, effective as of January 30, 2023. Roberts is filling the board seat recently vacated by Tim Campos who stepped down due to his increase of time commitments related to his new role as Chief Information Officer at Apple (AAPL). Roberts has over 35 years of technology, change management, and entrepreneurial experience and is currently an investor, business, and technology advisor. Prior to his current roles, Roberts worked for over 15 years at healthcare, retail and pharmacy group, Walgreens Boots Alliance (WBA) culminating in seven years as Global Chief Information Officer based in Chicago.

09:01 EST Hyundai Motor America reports January total sales of 52,001 units, up 9% y/y - Hyundai Motor America reported total January sales of 52,001 units, an 9% increase compared with January 2022 and the third consecutive month for record total sales. Hyundai set total sales records in January for Venue (+7%), Elantra HEV (+574%), IONIQ 5 (+57%), Santa Fe HEV (+191%), Palisade (+6%), Kona EV (+334%) and Kona N (+49%). January was an all-time best-ever retail and total sales month for the Elantra N. Hyundai fleet sales were 7.2% of total volume for the month.

08:55 EST Bright Green Corp trading halted, news pending

08:50 EST Veracyte: Data show Afirma testing may help patients with thyroid nodules care - Veracyte announced that data published in Frontiers in Endocrinology provide new insights into the frequency and risk of malignancy ROM associated with thyroid stimulating hormone receptor TSHR mutations in indeterminate thyroid nodules. The findings, which were derived from analyses of Veracyte's comprehensive thyroid nodule database of whole transcriptome sequencing, suggest that the use of Afirma testing could help inform diagnoses and personalized treatment decisions for patients with thyroid nodules. "We wanted to assess the frequency and risk of malignancy of TSHR mutations in indeterminate thyroid nodules, as well as how the risk of malignancy differs among those nodules classified by the Afirma Genomic Sequencing Classifier as suspicious for cancer versus benign," said Joyce Shin, M.D., endocrine surgeon and surgical director of the Thyroid Center ..." "These findings underscore the significant potential of our expansive thyroid nodule database and whole-transcriptome capabilities to derive insights that may further enhance the ability of Afirma testing to help personalize care for patients with thyroid nodules," said Joshua Klopper, M.D., Veracyte's medical director, Endocrinology.

08:49 EST Global Water Resources completes acquisition of Farmers Water Co. - Global Water Resources has completed the previously announced acquisition of Farmers Water Co., a subsidiary of Farmers Investment Co. located in Pima County, Arizona. The acquisition adds approximately 3,300 active water service connections and 21.5 square miles of Certificate of Convenience and Necessity service area in the Town of Sahuarita and the surrounding unincorporated area of Pima County. It has increased Global Water's total active water service connections in Pima County to nearly 5,000. The primarily residential connections are in close proximity to the service areas of Global Water's previously acquired Las Quintas Serenas, Francesca, Mirabell, and Red Rock water companies. These areas fall within the Arizona Sun Corridor, a megaregion that is expected to double in population by 2040.

08:47 EST Peloton not forecasting spike in churn rate

08:47 EST Peloton still sees revenue for the year to resemble seasonality of FY22 - Comments taken from Q2 earnings conference call.

08:45 EST Puma's Nerlynx included in NCCN guidelines for HER2-positive breast cancer - Puma Biotechnology announced that the National Comprehensive Cancer Network or NCCN, Clinical Practice Guidelines in Oncology for Breast Cancer were updated to include an addition involving neratinib NERLYNX . The updated NCCN Practice Guidelines for Breast Cancer include neratinib combinations as category 2B potential targeted therapies for patients with ER+/HER2- or ER-/HER2- metastatic breast cancer and activating mutations in the HER2 gene as detected by next generation sequencing of tumor tissue or ctDNA..." ...Additionally, in its recent update, NCCN included dose escalation in the neratinib dosing schedule for recurrent unresectable or metastatic breast cancer. The neratinib dose escalation schedule was previously included in the 2022 NCCN Guidelines for Breast Cancer under preoperative/adjuvant therapy regimens as an approach to improve the tolerability of neratinib in the treatment of adjuvant HER2-positive breast cancer. This latest update aligns with the labeling supplement to the U.S. Prescribing Information approved by the U.S. Food and Drug Administration in June 2021, which incorporated the use of NERLYNX dose escalation as evaluated in the Phase II CONTROL study. Alan H. Auerbach, Chief Executive Officer and President of Puma, said, "We are pleased with the additional inclusion of neratinib in the NCCN Guidelines for Breast Cancer for patients with HER2 activating mutations. Physicians use the NCCN Guidelines as the standard resource for determining the best course of treatment for patients. We believe the updated NCCN guidelines will increase awareness, which will help assist patients, their caregivers and their healthcare providers in making informed decisions while treating this significant unmet need in advanced breast cancer."

08:43 EST Jupiter Wellness appoints Hector Alila to board of directors - Jupiter Wellness announced that Dr. Hector Alila has rejoined its Board of Directors with the specific responsibility of building a Technical Advisory Board. He was most recently at Esperance Pharmaceuticals where he guided the clinical development of novel targeted cancer therapeutics.

08:42 EST Invacare commences chapter 11 bankruptcy, enters RSA - Invacare announced actions to strengthen the company and position it for long-term success. To facilitate its financial restructuring, the company has entered into a restructuring support agreement, or RSA agreement, with substantially all of its debt holders, including its term loan lender, all of the holders of convertible senior secured notes, and holders of a majority of its convertible senior unsecured notes. The agreement provides for a significant reduction of the company's debt balance and a substantial new money investment, which will enhance the company's liquidity, thereby enabling it to invest for future growth. Specifically, the transactions agreed to in the RSA contemplate a substantial reduction of the company's funded debt by approximately $240M. In addition, the RSA includes a backstop for a rights offering to holders of claims on account of the company's unsecured notes and holders of general unsecured claims, providing the company with $60 million of equity capital to repay certain of its debt obligations and facilitate the company's transformation plan. To effectuate the transactions contemplated by the agreement, Invacare and two of its U.S. based subsidiaries commenced voluntary Chapter 11 cases in the United States Bankruptcy Court for the Southern District of Texas. Invacare's other businesses throughout the rest of the world remain strong and are not included in these filings. The company does not anticipate these filings to impact its ability to manufacture and deliver products to its customers globally.

08:38 EST Peloton: Precor meets significant need in commercial marketplace - Peloton said earlier that it plans to change course, injecting new leadership, rightsizing Precor's cost structure, with the goal of restoring its growth.

08:37 EST Trinseo announces distribution agreement with Omya, no terms - Trinseo announces a distribution agreement with Omya, a leading global producer of industrial minerals and worldwide distributor of specialty chemicals. Under the terms of the agreement, Omya will provide high-quality ABS and PC/ABS resins to Trinseo automotive and mobility customers in North America starting February 1, 2023. The materials are offered under Trinseo's well-known brands MAGNUM ABS Resins and PULSE PC/ABS Resins.

08:36 EST KULR Technology retains Integrous Communications - KULR Technology Group announced that it has retained Integrous Communications as its investor relations advisor. Integrous Communications will assist KULR with communicating its corporate, financial and investor developments to current shareholders and prospective investors, while enhancing awareness of the Company's story within the capital markets. Mark Komonoski, Partner at Integrous Communications, will be the Company's primary investor contact.

08:35 EST Reliance Global adds real-time, life insurance quotation tool to platforms - Reliance Global Group announced that it has added a real-time, life insurance quotation tool to both its RELI Exchange and 5Minuteinsure.com platforms. The tool displays life insurance quotes from more than 15 life insurance companies, and builds upon the Company's successful home and auto insurance offerings.

08:34 EST Splunk to cut 4% of global workforce, mostly in North America - In a regulatory filing, Splunk said that on February 1, the company announced a plan of reorganization involving approximately 4% of the company's global workforce, mostly in North America. This decision is another step in a broader set of proactive organizational and strategic changes that include optimizing the company's processes, cost structure and how the company operates globally to ensure the company continues to balance growth with profitability through these uncertain times and drive success over the long term. The company estimates that it will incur approximately $28M in charges and future cash expenditures in connection with the Plan, consisting primarily of cash expenditures related to severance payments, certain retention payments, employee benefits and employee transition costs, as well as non-cash charges for share-based compensation expense. The company expects predominantly all of the actions associated with the Plan to be completed, and substantially all the associated charges and cash expenditures to be incurred, in the first quarter of fiscal year 2024, subject to local law and consultation requirements.

08:33 EST InterCure terminates acquisition agreement with Cann Pharmaceutical - InterCure announces that, further to the merger agreement with Cann Pharmaceutical dated as of February 13, 2022, pursuant to which and subject to its terms, InterCure was to acquire 100% of the issued and outstanding shares of Better, and further to the Company's press release dated November 23, 2022 regarding the fundamental disagreements between the parties, that the closing conditions contained in the Agreement were not met and the Agreement was terminated. In accordance with the terms of the Agreement, the Agreement terminates automatically if the closing conditions and the merger are not completed by 5:00 pm on 31st of January 2023. Accordingly, and in light of the fact that the closing conditions were not met by such date, the Agreement was automatically terminated. Intercure is owed significant amounts loaned and advanced to Better, and since the Agreement was terminated, it intends to recover said amounts under all legal means available to it.

08:32 EST Versus to partner with Resolve to bring AI-powered credit, debit products - Versus Systems announced that it will partner with automated debt collection and artificial intelligence company Resolve Debt to bring gamification and interactive elements to Resolve's existing AI-powered credit and debt management products and customers, with the goal of addressing a portion of the $4.5 trillion US consumer debt market. Versus uses interactivity and rewards to make advertising and entertainment more engaging, driving consented first-party data for brands that want to connect with their consumer base. "This is a unique opportunity for Versus," said Matthew Pierce, Founder and CEO of Versus Systems. "We get to partner with experts and new generation technology innovators in fintech, payments, and generative AI who have successfully built significant fintech and AI businesses in the past. It's a new application for products and methods that we have long believed in. Our entire product suite has always been built around the effectiveness of interactivity and rewards to incentivize end users. Adding this expertise to Resolve's generative AI platform will help more companies provide appropriate repayment solutions to consumers cost effectively, at scale."

08:25 EST XS Financial reports over $147M in capex financing commitments - The company said, "Advancing its position as a leading CAPEX financing company to the legal U.S. cannabis industry, XS Financial is pleased to announce that for the year ended December 31, 2022, the Company completed $68.0 million in new lease transactions, a 167% YoY increase. In addition, XSF closed on new commitments of $147.4 million, a 36% YoY increase, which will significantly drive new lease transactions in 2023. XSF made significant progress in increasing its funding capacity while reducing its incremental borrowing cost. In 2022, the Company closed an upsized $39 million line of credit with an FDIC-insured bank and received its final $10 million funding tranche from convertible notes the previous year. In addition, due to the increased funding capacity, XSF retired its preexisting line of credit from a private credit fund, which had a higher borrowing rate than its new credit facility. This decrease in borrowing rate helped the Company achieve its first quarter of positive Net Distributable Earnings in 3Q22."

08:21 EST Edesa Biotech receives regulatory approval for Phase 2 vitiligo study - Edesa Biotech announced that it has received approval from Health Canada for a Phase 2 clinical study of the company's EB06 monoclonal antibody candidate as a treatment for vitiligo. Edesa's drug targets autoreactive T cells that destroy the pigment-producing cells of the epidermis. Specifically, EB06 binds to chemokine ligand 10 and inhibits the interaction of CXCL10 with its receptor. CXCL10 is highly expressed in vitiligo patients in both skin and serum, and CXCL10 is implicated in both the initiation of the disease and the maintenance of vitiligo lesions. Results from 65 subjects in three previous clinical studies demonstrated that EB06 produced the pharmacodynamic /biological activity required to address the dysfunctional immune response associated with vitiligo, and was generally safe and well tolerated. Preclinical studies have also demonstrated that neutralization of CXCL10 prevented and reversed depigmentation. As planned, the Phase 2 study protocol approved by Health Canada will evaluate the safety and efficacy of EB06 versus placebo in adults with moderate to severe non-segmental vitiligo. Patients will receive intravenous infusions of either EB06 or placebo during the treatment period, followed by a follow-up period. Approximately 120 adult subjects will be included in the double-blind, placebo-controlled study at up to approximately 25 investigational centers in Canada. The primary endpoint will be improvement from baseline on the Face Vitiligo Area Scoring Index, a quantitative clinical tool that estimates the overall area of vitiligo patches and the degree of macular re-pigmentation within these patches over time.

08:18 EST Genetic Technologies forms strategic alliance with Qiagen - Genetic Technologies (GENE) announced that the Company is forming a strategic alliance with QIAGEN (QGEN). The alliance will establish and develop a 'Centre of Excellence' facility in Australia initially servicing Australia and New Zealand with potential for expansion, showcasing the Life Science and Diagnostics expertise of both organizations throughout the region. The partnership will further enhance GTG's reputation as a regional leader in precision medicine in predicative and consumer genomics, utilizing QIAGEN technologies.The relationship is expected to open a wide range of new commercial opportunities for GTG with enhanced automation capability and increased capacity supporting long-term revenue growth. Additionally, this initiative will unlock the Australian reimbursable market for all testing categories, including the geneType hereditary cancer test. This will make the geneType Breast, Ovarian and Colorectal cancer tests the most comprehensive offering in the market later in 2023. Gaining reimbursement coverage for geneType cancer assessment tests is expected to accelerate the adoption of these tests by General Practice clinics where patients are able to undertake the test with minimal out-of-pocket expenses. QIAGEN will support the enhancement of GTG capabilities through software, hardware, consumable and technical solutions, including: the reagents and QIAGEN's proprietary QCII software to complete Next Generation Sequencing validation in house. The rollout will include QIAGEN's QIAseq targeted DNA Pro Sample to Insight solutions for NGS Oncology and customized inhouse data analysis tools to provide sample to result service for GTG customers; collection devices, hardware, reagents and panels to equip GTG with the required laboratory scale to perform tests in-house; capability to multiplex on different scalable platforms; and provide technical support and the establishment of protocols for GTG to perform the tests for NATA accreditation for QIAGEN related Technologies.

08:17 EST Akerna regains compliance with NASDAQ continued listing requirement - Akerna announced that the company has received confirmation from The Nasdaq Stock Market that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2) and currently meets all other applicable criteria for continued listing. On May 24, 2022, Staff of Nasdaq notified the Company that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Listing Rules of The Nasdaq Stock Market. On January 27, 2023, Staff notified the company that for the last 10 consecutive business days, from January 12 to January 26, 2023, the closing bid price of the Company's common stock has been at $1.00 per share or greater.

08:15 EST Cidara Therapeutics, WuXi XDC expand collaboration for CD73 program - Cidara Therapeutics announced an expansion of their existing collaboration under which WuXi XDC will provide investigational new drug-enabling chemistry, manufacturing and controls development services for Cidara's CD73 oncology DFC program. Cidara's lead oncology candidate, renamed CD421, targets CD73 in the adenosine pathway, which contributes to immune evasion in solid cancers by flooding the tumor microenvironment with adenosine, a potent immune cell suppressor. CD73 is highly expressed on a variety of tumor and stromal cells as well as immunosuppressive cell populations, such as regulatory T cells and myeloid-derived suppressor cells. Cidara's lead CD73 DFC is designed to address the potency, efficacy, pharmacokinetic and safety limitations of small molecule and monoclonal antibody candidates targeting CD73. Cloudbreak DFCs stably couple highly potent small molecules or peptides to a proprietary variant of a human antibody fragment. As a result, DFCs are long-acting, and are designed to directly inhibit specific disease targets. DFCs can be tuned to engage the immune system or to be immune silent, expanding the breadth of indications that can be targeted. Immune active DFCs can attract an immune response against cancer cells to maximize disease eradicating activity, while immune silent DFCs allow for expansion into cancer indications where immune system engagement could result in host toxicity. Financial terms of the agreement were not disclosed.

08:14 EST Sportradar appoints Riviere as Chief People Officer - Sportradar announced the appointment of Severine Riviere as Chief People Officer, effective immediately. Riviere, who brings two decades of experience in global human resource management and business transformation to the role, will be responsible for all aspects of Sportradar's human resources strategy. Riviere joins Sportradar from Fyffes International where she served as Chief Human Resources Officer and launched strategic plans to improve operational efficiency and transform culture.

08:13 EST Akoya Biosciences to present results from spatial multiomics study - Akoya Biosciences announced that the company will present results from a novel same-section, spatial multiomic study at the Advances in Genome Biology and Technology Annual Meeting being held in Hollywood, Florida from February 6-9, 2023. Leveraging the high-speed imaging platform, PhenoCycler-Fusion, company scientists to showcase how imaging both RNA and protein biomarkers simultaneously, in a single tissue section, can give a more complete picture of tumor biology. Protein and RNA biomarkers play complementary roles in defining cell phenotypes and cell states, respectively, in a tissue sample. Proteins are the key effectors of cell function and detecting cell surface protein markers can serve as a ground truth for cell identity. RNA markers such as cytokines and chemokines can provide an insight into signaling pathways that result in changes in cell states, arising from interactions within the tumor microenvironment. Measuring both analytes within the same tissue can give researchers an accurate picture of tumor progression and response to therapy. First unveiled at the AGBT Annual Meeting in 2022, the company's RNA chemistry was combined with the company's industry-leading proteomics offering in a novel multiomic study featuring 46 samples, 23 tissue types and simultaneous detection of RNA and protein biomarkers from each section. The ability to scale the chemistry across multiple samples and a diversity of tissue types is a key requirement for discovering robust biomarker signatures. The study was conducted on the PhenoCycler-Fusion System which enables rapid imaging of whole slides at single-cell resolution. In addition to the speed of imaging, the system has a proprietary file compression algorithm that can reduce file sizes from terabytes to gigabytes. This powerful combination makes it easier for researchers to scale up their studies with higher weekly throughput, while reducing data storage costs.

08:12 EST Getaround receives continued listing standard notice from NYSE - Getaround announced that on January 30, it received notice from the New York Stock Exchange indicating that Getaround is not in compliance with NYSE's continued listing standards because the average closing price of Getaround's common stock was less than $1.00 over a consecutive 30 trading-day period. The notice does not result in the immediate delisting of Getaround's common stock from the NYSE. Getaround intends to notify NYSE of its intent to cure the stock price deficiency and return to compliance with the NYSE continued listing standards. Under NYSE rules, Getaround has a period of six months from receipt of the notice to cure the stock price deficiency and regain compliance with the NYSE continued listing standards. Getaround's common stock will continue to be listed and trade on the NYSE during this cure period, subject to Getaround's compliance with other NYSE continued listing standards.

08:10 EST Blink Charging retains ShareIntel to investigate illegal shorting activity - Blink Charging announced that it has entered into a service agreement with Shareholder Intelligence Services, a patented compliance driven SAAS retained by public companies to track shareholder ownership and monitor critical broker-dealer and shareholder movement, to investigate and report on potential illegal naked short selling activities of Company stock, among other suspected trading violations. In its review of unusual trading patterns, the Company believes that certain individuals and/or companies may have engaged in manipulative and/or suspected illegal trading practices that may have artificially depressed its share price. The Company suspects that its actual short position may be greater than the 30+% reported to FINRA and the public. There is great concern in today's market environment regarding the potential targeting of Blink Charging and other publicly traded companies in a market manipulation scheme involving illegal naked short selling of Company stock. The Company finds such suspected manipulation completely unacceptable as it distorts the value of the targeted Companies and negatively impacts the shareholders who have invested their hard-earned money.

08:09 EST WillScot Mobile Mini completes divestiture of U.K. storage business - WillScot Mobile Mini announced it has completed the previously announced divestiture of its UK Storage segment to Algeco UK Holdings Limited, a member of the Modulaire Group, effective January 31, 2023. The Company received approximately $410M from the sale, which will be used to support ongoing reinvestment in the Company's core Modular and Storage operating segments and other capital allocation priorities. The UK Storage segment will be reported as discontinued operations in the Company's Q4 2022 financial filings, and management will provide 2023 financial guidance excluding the UK Storage segment in the Q4 2022 earnings press release on February 21, 2023.

08:08 EST Kingstone estimates Q4 net pre-tax catastrophe losses $3.66M - Kingstone announced that Kingstone Insurance Company, its wholly-owned subsidiary, estimates net pre-tax catastrophe losses for the fourth quarter of 2022 of $3.66 M or 12.0 points of net earned premium. Catastrophe losses for the quarter primarily resulted from Winter Storm Elliott, which significantly impacted the Northeast, including the states in which Kingstone operates. "The footprint of Winter Storm Elliott expanded to each of the geographies in which Kingstone operates, including New York where we have the majority of the Company's business. Accordingly, our business was impacted by severe and widespread weather-related residential property losses, consistent with industry trends," said Barry Goldstein, Kingstone's Chairman and Chief Executive Officer. Goldstein continued, "I am delighted to share that Kingstone achieved a milestone in 2022 with annual direct written premiums exceeding $200 million for the first time. The increase in our premiums at a higher rate than the growth in exposures is representative of the progress we are making on our go-forward plan to return Kingstone to profitability."

08:07 EST Healthcare Triangle accelerates FCMC's MEDITECH expanse implementation - Healthcare Triangle announced that they have successfully helped Floyd County Medical Center, FCMC, in accelerating their MEDITECH Expanse implementation. Floyd County Medical Center is a 25-bed critical access hospital and rural health clinic based out of Iowa. They wanted to leverage a unified MEDITECH Expanse solution as an enabler for operational excellence and looked for MEDITECH expertise to help them go forward with a successful MEDITECH Expanse EHR implementation. The Medical Center chose to partner with Healthcare Triangle due to the company's extensive experience and successful track record in implementing the MEDITECH Expanse system.

08:06 EST Agile Therapeutics provides clinical update on Twirla, pipeline evaluation - Agile Therapeutics provided an update on the Twirla post-marketing studies and status of its ongoing evaluation of the Company's pipeline. Twirla Post-Marketing Studies: As part of Twirla's approval, the United States Food and Drug Administration required the Company to conduct a long-term prospective, multi-center clinical post-marketing requirement study comparing the risks of venous thromboembolism and arterial thromboembolism in new users of Twirla to new users of combined hormonal contraceptives and Ortho Evra generic patches. In January 2023, the FDA agreed with the Company's proposal to address this PMR using electronic health records and insurance claims from a large database from multiple healthcare systems. The FDA also agreed to extend the study timelines. Under these new milestones, interim safety data reporting to the FDA is due in November 2029, and the final PMR study report is scheduled to be submitted to the FDA in November 2035. Status of Pipeline Evaluation: As previously disclosed, all work on Agile's pipeline has been halted since 2021 as the Company concentrates its efforts the commercialization of Twirla. Commercializing Twirla remains the Company's primary focus into 2023; however, the Company has continued to evaluate the potential eventual advancement of the AG200-15 Extended Regimen and the progestin-only patch. "Our primary focus since the launch of Twirla has been the commercial growth of Twirla. We believe, however, that we have potential value in our pipeline and have been evaluating how to prioritize the eventual development of our product candidates. While we do not currently expect to invest significant funds in our pipeline in 2023 as we continue to focus on maintaining capital efficiency and keeping tight control on our operating expenses, we have been using creative approaches to advance the evaluation of our pipeline and prepare for a time when we can move forward," stated, Al Altomari, Chairman and Chief Executive Officer of Agile Therapeutics.As part of its evaluation of the AG200-15 Extended Regimen, Agile performed an analysis with a simulated pharmacokinetic model that was used to predict the systemic levonorgestrel and ethinyl estradiol exposure of Twirla if used for twelve consecutive weeks. Data from a previously published clinical phase 1, open-label, randomized clinical trial2 was used for the PK model simulation, which included 36 healthy individuals who used a standard Twirla regimen for three consecutive weeks.

08:05 EST Miromatrix Medical, Baxter announce collaborative ALF research agreement - Miromatrix Medical (MIRO) and Baxter (BAX) announced a collaborative research agreement to help support additional treatment options for patients with acute liver failure, or ALF, in need of organ support therapies. As part of the collaboration, Miromatrix has created a new liver therapy called miroliverELAP that combines a Miromatrix single-use bioengineered liver with Baxter's PrisMax system. Miromatrix submitted an investigational new drug, or IND, application for miroliverELAP to the FDA in November 2022, which appears to be the first IND for a bioengineered organ. Miromatrix intends to commence a Phase I clinical trial using miroliverELAP to treat patients suffering from ALF, following FDA's decision that the trial may proceed. Baxter is both a collaborator and shareholder of Miromatrix.

08:04 EST Mersana Therapeutics initiates expansion portion of UPGRADE-A trial - Mersana Therapeutics announced that patient dosing is underway in the expansion portion of its UPGRADE-A clinical trial of UpRi in combination with carboplatin in platinum-sensitive ovarian cancer. UpRi is Mersana's first-in-class NaPi2b-targeting ADC with a novel scaffold-linker-payload designed to enable a high drug-to-antibody ratio and controlled bystander effect. "While the combination of carboplatin and paclitaxel has historically served as the standard of care in early lines of therapy for platinum-sensitive ovarian cancer, it is limited by distinct tolerability and side effect challenges that can include severe neutropenia, peripheral neuropathy and alopecia," said Dr. Arvin Yang, Senior Vice President and Chief Medical Officer of Mersana Therapeutics. "With UPGRADE-A, we are investigating the potential benefits of replacing paclitaxel with UpRi in the induction phase of treatment and then continuing UpRi as maintenance monotherapy. We are pleased to enter this exciting new phase of the trial." Mersana expects to report interim data from UPGRADE-A in the second half of 2023.

07:47 EST Equifax acquires Food Industry Credit Bureau from Profile Credit - Equifax announced the acquisition of The Food Industry Credit Bureau, a provider of credit information for the food industry in Canada, from Profile Credit. The company said, "This acquisition expands the breadth of commercial credit insights available to Equifax customers in Canada and worldwide, making differentiated data insights on over 90 percent of the Canadian food industry available...Based in Montreal, The Food Industry Credit Bureau from Profile Credit works in partnership with over 1,000 companies, such as food and beverage service providers, meat and poultry processing, and distribution to provide up-to-date credit data on over 200,000 businesses. The bureau has one of the most comprehensive platforms for bringing together members of the agri-food industry to solve collectively for the challenges and specific dynamics of the sector." The Profile Credit credit bureau business is now part of Equifax Canada. The acquisition is not anticipated to have a material impact on 2023 Equifax financial results.

07:42 EST Apyx Medical announces FDA 510k submission for Renuvion use post liposuction - Apyx Medical announced it has submitted a 510 k premarket notification, 510 k submission, for the Renuvion APR Handpiece to the U.S. Food and Drug Administration, FDA , supported by a clinical study and real-world evidence. The 510 k submission is intended to expand Renuvion's indications for use to include a specific indication for the use of the Renuvion APR Handpiece for the coagulation of subcutaneous soft tissues where needed, following liposuction. "We are pleased to announce the submission of this request for 510 k clearance for a new clinical indication, which is intended to enable Apyx Medical to market and sell our Renuvion APR Handpiece for use following liposuction," said Charlie Goodwin, President and Chief Executive Officer. "This 510 k submission leverages the substantial history of safe use of the Renuvion APR handpiece following liposuction procedures, and as such, Apyx Medical was able to assess the device based on a large set of retrospective chart reviews. Importantly, our analysis of Renuvion treatment adverse events, when compared to the real-world evidence gathered for liposuction treatments in the literature review, demonstrated that there are no new or increased risks for Renuvion procedures following liposuction procedures compared to liposuction alone."

07:38 EST Cybin gets okay for 1st-in-human dosing of DMT Molecule CYB004 for anxiety - Cybin announces that it has received approval from an independent ethics committee in the Netherlands to initiate first-in-human dosing of its proprietary deuterated N,N-dimethyltryptamine , DMT, molecule CYB004 through a protocol amendment to its ongoing CYB004-E Phase 1 trial. This clinical advancement marks the first time a deuterated DMT molecule will be evaluated in humans and further reduces Cybin's time-to-clinic with CYB004...studies also demonstrated that IV CYB004 has a longer duration of effect compared to DMT, indicating the potential to extend the therapeutic window and provide better dose optimization. By maximizing CYB004 as a deuterated molecule and improving upon the bioavailability of DMT, CYB004 has the potential to offer more convenient dosing methods via inhaled, subcutaneous, or intramuscular routes of administration. "This is a major milestone for our CYB004 program and for better understanding the potential therapeutic benefits of our proprietary deuterated DMT molecule for the treatment of generalized anxiety disorder," said Doug Drysdale, Cybin's Chief Executive Officer. " ..The Company plans to evaluate CYB004 for the treatment of generalized anxiety disorder with or without major depressive disorder. Cybin will provide additional information on its CYB004 program, including an update on the Phase 1 CYB004-E trial, at its upcoming virtual R&D Day on February 28.

07:37 EST React Gaming to integrate AI into Compete.gg, LOOT.BET platforms - React Gaming Group announces its 2023 plans to enhance the capabilities of its online esports tournament and betting platforms, Compete.gg and LOOT.BET, through the integration of artificial intelligence applications and machine learning techniques. "Esports is a large and growing market with revenues that are expected to reach $1.87 billion in 2025, according to market analytics firm Statista. As this booming industry grows, AI is widely seen as having the potential to bring about significant revenue opportunities in the next decade. AI's ability to automate repetitive tasks, make smart decisions, and analyze large amounts of data faster than humans, makes it a valuable tool for businesses across various industries, including gaming and esports. In the online esports space, AI can help improve tournament organization and player engagement, provide valuable insights for sponsors, and streamline betting and wagering processes, amongst many other applications that could benefit Compete.gg and LOOT.BET. This is why we will focus in 2023 on enhancing our AI capabilities in both our online esports platforms," said Leigh Hughes, CEO of React Gaming.

07:35 EST Evelo Biosciences provides clinical, business updates - Evelo Biosciences announced updates to its clinical pipeline as well as business updates. "We observed an unusually high placebo response rate in the first three cohorts of the EDP1815 Phase 2 atopic dermatitis study, resulting in a missed primary endpoint," said Simba Gill, Ph.D., CEO of Evelo. "We are working through the data to understand the very high placebo rates observed in the trial, which occurred with greater prevalence in certain geographic regions. The fourth cohort of the trial, which is designed to test the faster release formulation, is fully recruited and we expect to report data from this cohort in the second quarter of this year. The results of this cohort will inform our path forward in atopic dermatitis." Dr. Gill continued, "We have recently completed interactions with the FDA, EMA and MHRA around proposed Phase 3 plans in psoriasis. Based on their feedback, we believe we have a clear path towards a global registration program for EDP1815 in psoriasis. As a reminder, EDP1815 was well-tolerated and demonstrated positive efficacy results in a Phase 2 psoriasis clinical trial, supporting further development of EDP1815 for the broad treatment of psoriasis patients with mild and moderate disease for which there are few treatment options. Additionally, we are pleased to announce that we have begun dosing in the first clinical trial of a microbial extracellular vesicle," Dr. Gill said. "EVs have the potential to be a new type of potent SINTAX-based medicine and we are looking forward to reporting Phase 2 data for EDP2939 in psoriasis expected in the second half of this year." Clinical and Business Updates: EDP1815 Phase 2 in Atopic Dermatitis - Topline Data from First Three Cohorts; Data from Fourth Cohort Expected 2Q 2023. EDP2939 in Psoriasis - Initiation of Dosing in First EV Product Candidate: Dosing of healthy volunteers in Part A of the trial began in January 2023 and the Company anticipates dosing of patients in Part B to commence later in 1Q 2023. Phase 2 data in the cohort of patients with psoriasis is still expected in the second half of 2023.

07:34 EST TC Energy sees $14.5B in costs to complete Coastal GasLink Project - TC Energy Corporation announced updated cost estimates for the Coastal GasLink Project. The Project continues to face material cost pressures that include challenging conditions in the Western Canadian labour market; shortages of skilled labour; impacts of contractor underperformance and disputes; as well as other unexpected events like drought conditions and erosion and sediment control challenges. A comprehensive cost and schedule risk analysis was conducted to assess current market conditions and potential risks and uncertainties facing the remaining project scope. As a result of the CSRA, TC Energy's estimate of the costs to complete the Project has increased to approximately $14.5 billion. This estimate excludes potential cost recoveries and incorporates contingencies for certain factors that may be outside of the Company's control such as labour conditions; contractor performance; and weather-related events. TC Energy expects to fund the incremental revised project costs and is actively pursuing cost mitigants and recoveries that may partially offset a portion of these costs, some of which may not be conclusively determined until after the Project is in service. Coastal GasLink is working closely with its prime contractors on implementing productivity improvement strategies targeting mechanical completion by year-end 2023, with commissioning and clean-up work continuing into 2024 and 2025. The CSRA review also considered the potential impact of an extension of construction well into 2024. In that event, costs would increase further by up to $1.2 billion. Due to the increase in the expected cost of the Project and the additional funding required, TC Energy will recognize an impairment to its equity investment in Coastal GasLink LP in its fourth quarter 2022 financial results. The Coastal GasLink Project continues to make significant progress having reached approximately 83 per cent overall completion. The entire route has been cleared, grading is more than 94 per cent complete and over 485 km of the approximately 670 km pipeline has been backfilled with restoration activities underway in many areas. The Wilde Lake Compressor Facility has commenced commissioning work with the introduction of natural gas expected in March, representing another significant milestone in reaching our targeted mechanical completion later this year. Once complete, Coastal GasLink will be Canada's first direct link for LNG deliveries that will further support displacing 60 to 90 million tonnes of CO2 emissions annually, an important step along the energy transition. TC Energy's overall 2023 capital expenditure outlook has been revised to approximately $11.5 to $12.0 billion, reflecting the deferral of certain project spending, expected cost-saving initiatives and incremental funding requirements associated with Coastal GasLink.

07:32 EST Society Pass boar approves up to $2M stock repurchase program - Society Pass announces that its Board of Directors has approved a stock repurchase program authorizing the repurchase of up to $2M of its common stock, commencing on 01 February 2023. Dennis Nguyen, Founder, Chairman and Chief Executive Officer, comments, "We are pleased to announce the approval of this share repurchase program, providing us with a significant tool to generate shareholder value. As of 31 December 2022, SoPa has approximately US$19 mn of cash and zero long-term debt. Given our closing stock price of $1.11 on 31 January 2023, our current undervalued market capitalisation presents an extremely attractive opportunity to buy our common shares at a significant discount to their intrinsic value. Our well capitalised cash position, which translates into approximately $0.70 per share, and strong revenue generation allow SoPa to build out our next generation fintech and e-commerce ecosystem in SEA through paradigm shifting acquisitions and fund this stock repurchase program." The Company engaged ThinkEquity LLC to purchase shares of the Company's common stock from time to time in the open market at prevailing market prices, in privately negotiated transactions or other means in compliance with applicable federal securities laws.

07:31 EST Annovis Bio announces filing of patent covering buntanetap administration - Annovis Bio announced the filing of a patent application that extends the breadth of its platform from neurodegenerative to neuropsychiatric indications: "Treatment of mental illness via administration of buntanetap and analogues." "Mental illnesses demonstrate abnormal levels of neurotoxic proteins. These neurotoxic proteins cause impairment in axonal transmission and inflammation, similar to what is seen in neurodegenerative diseases. In fact, axonal transport and synaptic transmission are severely impacted in neuropsychiatric disorders and our drug restores axonal transport and synaptic transmission," said Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis. "In Phase 2a trials of Alzheimer's disease and Parkinson's disease, treatment with buntanetap resulted in improved axonal and synaptic function as well as cognitive and functional health. Through its unique ability to inhibit a range of aggregating proteins, we believe that buntanetap has the potential to restore protein homeostasis and delay the advancement of a number of mental illnesses."

07:26 EST Laser Photonics to add IoT solutions to assist laser customers - Laser Photonics Corporation announced it plans to develop IoT Solutions to assist next-generation laser customers in accurately measuring crucial KPIs across all business lines.

07:23 EST Lifeist Wellness closes second tranche with Alumina Partners - Lifeist Wellness announced that it has completed a second tranche under its previously announced draw-down equity facility with Alumina Partners, an affiliate of New York-based private equity firm Alumina Partners, LLC. Gross proceeds to Lifeist were approximately $260,335. As previously announced, Lifeist and Alumina Partners entered into an equity financing facility of up to $8 million. Lifeist has the ability to draw down capital on an as-needed basis, minimizing dilution. In connection with the closing of the second tranche under the equity facility, Lifeist issued a total of 4,628,177 units at a price of $0.05625 per unit for gross proceeds of $260,335. Each unit consisted of one common share of Lifeist and one transferable share purchase warrant with each warrant exercisable to acquire one additional common share at a price of $0.09375 for a period of three years. The warrants are subject to an acceleration provision that allows the Company to give notice of an earlier expiry date if the 10-day volume weighted average price of the Company's common shares on the TSXV is equal or greater than $0.1875. The securities are subject to a hold period expiring on June 1, 2023. The proceeds of this second tranche will be used for general corporate purposes, including growth investments for the Mikra nutraceuticals business.

07:19 EST Matrix awarded 600,000 ethane tank engineering, procurement, construction - Matrix Service Company announced its subsidiary, Matrix Service, has been awarded the greenfield engineering, procurement, and construction of a 600,000 barrel cryogenic ethane storage tank for Enterprise Products along the Texas Gulf Coast. The project, which was taken into Matrix's backlog in the first quarter of Fiscal 2023, supports a continued demand for ethane in the global marketplace. Engineering for the storage tank will be completed by Matrix PDM Engineering. "We value our long-standing relationship with Enterprise and appreciate their trust and confidence in us to engineer and construct this critical infrastructure," Matrix Service President and CEO John R. Hewitt. "The global demand for ethane from the U.S. continues to increase because of its value as a petrochemical feedstock that can be broken down into ethylene, used in a wide variety of industrial, agricultural, and other applications. This greenfield infrastructure helps support that demand. As a leader in the engineering, construction, and maintenance of cryogenic infrastructure, Matrix is fielding a growing number of downstream project opportunities, including those for both ethane and ethylene."

07:17 EST Lantronix expands Open-Q family with SIP modules - Lantronix announced the expansion of its Open-Q family with its new entry-level Open-Q 2290CS and mid-tier Open-Q 4290CS System-in-Package chipset modules as well as the companion Open-Q AL2 Development Kit. The two SIP modules are footprint compatible, allowing for flexibility in hardware design choice. The SIP modules are based on the Qualcomm QCS2290 and QCS4290 System-on-Chip, utilizing Qualcomm Technologies' heterogenous compute expertise with multiple specialized processing cores. The new Open-Q SIP modules deliver powerful performance, vivid graphics, dynamic camera capabilities and a broad set of connectivity options.

07:15 EST American Lithium announces PEA results for Tonopah Lithium Claims - American Lithium announced the results of its maiden Preliminary Economic Assessment for the Tonopah Lithium Claims project located in the Esmerelda lithium district northwest of Tonopah, Nevada. This independent PEA was completed jointly by DRA Global and Stantec Consulting and demonstrates that the TLC project has the potential to become a substantial, long-life producer of low-cost lithium carbonate with the potential to produce either battery grade LCE or lithium hydroxide. The PEA base case envisions an initial 4.4 Million tonnes per annum processing throughput expanding to 8.8Mtpa. The PEA alternative case is identical, but with added production of high purity magnesium sulfate as a by-product over life of operations. TLC PEA Highlights: Pre-tax Net Present Value 8% $3.64 billion at $20,000/tonne LCE; After-tax NPV8% $3.26 billion at $20,000/t LCE; Pre-tax Internal Rate of Return of 28.8%; After-tax IRR of 27.5%; PEA mine and processing plan produces 1.46 Mt LCE LOM over 40 years; Pre-tax initial capital payback period 3.6 years; after-tax payback 3.8 years; Average LOM annual pre-tax cash flow: $435 million; annual after tax cash flow: $396 million; Initial Capital Costs estimated at $819 million; Total Capex estimated at $1,431 million; Sustaining Capital estimated at $792 million; Operating cost estimated at $7443/t LCE inclusive of power credits.

07:13 EST FDA approves Bausch Lomb & Modulight's ML6710i photodynamic laser - Bausch + Lomb and Modulight announced that the U.S. Food and Drug Administration FDA has approved the ML6710i photodynamic laser for equivalent use with Bausch + Lomb's VISUDYNE or verteporfin for injection photodynamic therapy,PDT, for the treatment of patients with predominantly classic subfoveal choroidal neovascularization, or the creation of abnormal choroidal blood vessels, due to Age-related Macular Degeneration ,AMD, 1 ML6710i is expected to be available for eye care professionals during the first half of 2023. "PDT continues to be an important treatment option for eye care professionals who are looking to treat patients with predominantly classic subfoveal choroidal neovascularization," said Christina Ackermann, president, Ophthalmic Pharmaceuticals, Bausch + Lomb

07:12 EST Apollo Silver reports further assay results from Phase 2 drilling at Calico - Apollo Silver reports further assay results from Phase 2 of the 2022 Drill Program at the Calico Silver Project located in San Bernardino County, California. Resource infill drilling results continue to deliver high grade silver intercepts. Results below include: 197 grams per tonne Ag over 61.0 metres from surface and 135 g/t Ag over 85.5 m from 5.5 m down hole. Apollo is now in possession of all silver assay results for drill holes that targeted the 2022 Waterloo mineral resource block model, which defined 116 million ounces of silver at 93 g/t Ag at a 50 g/t cut-off grade. The 2023 resource estimation work program is proceeding as scheduled with results anticipated in early March. Temporary Use Permit extension for one year period for planned future drilling at Waterloo has been granted by San Bernardino County. New significant intercepts include: SILVER: 197 g/t Ag over 61.0 m from surface, including; 273 g/t Ag over 18.0 m from 35.5 m down hole, and including; 508 g/t Ag over 1.5 m from 41.5 m down hole; 135 g/t Ag over 85.5 m from 5.5 m down hole, including; 417 g/t Ag over 4.5 m from 28.0 m down hole; 254 g/t Ag over 1.5 m from 46.0 m down hole; 298 g/t Ag over 3.0 m from 49.0 m down hole; 96 g/t Ag over 32.5 m from surface, and 84 g/t Ag over 31.5 m from 44.5 m depth down hole; 129 g/t Ag over 40.0 m from surface, including; 275 g/t Ag over 1.5 m from 5.5 m depth down hole, and including 322 g/t Ag over 1.5 m from 23.5 m depth down hole.

07:12 EST Tonix Pharmaceuticals announces research agreement with UMB to study TNX-1500 - Tonix Pharmaceuticals announced that it has entered into a sponsored research agreement with the University of Maryland, Baltimore, UMB, for the prevention of rejection in heart xenograft transplantation in animals utilizing TNX-15001, an Fc-modified humanized monoclonal antibody directed against CD40-ligand. UMB's preclinical studies will utilize genetically-modified porcine hearts supplied by Revivicor, Inc., a subsidiary of United Therapeutics Corporation. "We are excited to collaborate with the University of Maryland and Dr. Mohiuddin on the development of TNX-1500 for the prevention of rejection in xenograft transplantation," said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. "TNX-1500 is a third generation anti-CD40L monoclonal antibody that has been designed by protein engineering to decrease FcgammaRII binding and to reduce the potential for thrombosis. Previous preclinical studies in non-human primates demonstrated that TNX-1500 showed activity in preventing allograft and xenograft organ rejection and was well tolerated. A positive result from this study would potentially help support an Investigational New Drug application and human clinical studies. Despite exciting advancements in the field of xenotransplantation, better therapeutics are needed to prevent xenograft organ rejection," said Dr. Mohiuddin. "Several lines of research indicate that anti-CD40L is required for long term xenograft acceptance. We are excited to collaborate in support of developing an effective immunosuppression regimen for patients requiring xenograft transplantation."

07:10 EST Auddia creates proprietary audio content hosting, streaming system - Auddia announced that it has created a proprietary audio content hosting and streaming system that supports the unique and exclusive demands offered in its flagship mobile app, faidr. The Company launched faidrRadio, currently only available in its iOS product, which includes both Music Casts and Music Stations on January 24, 2023. Music Casts will be added to its Android app later in Q1. To host and distribute the dynamic content within Music Casts, the Company has created a proprietary music hosting and streaming system that supports a unique method of music and talk-segment delivery. This proprietary system can host, stream and track music plays while providing novel controls to listeners and can also accommodate music podcasts that play entire songs within episodes while complying with existing music-streaming guidelines. Auddia will be launching podcasts in the app before the end of Q1 to combine differentiated ad-free listening and exclusive content with podcasting to complete the first phase of the Superapp strategy.

07:08 EST Moving iMage Technologies announces first e-sports orders from SNDBX - Moving iMage Technologies announced it shipped its first two MovEsports for SNDBX eight-cart gaming systems for the Esports market to a movie exhibitor in Wyoming. "Last April, we announced a partnership with SNDBX to bring amateur Esports leagues to the local big screen," said Frank Tees, vice president, technical sales support. "With a massive, inclusive community for all ages and abilities, Esports in cinemas builds on a nationwide tradition of participation in and watching games for fun. SNDBX is innovating on this trend by building a program tailored to cinema exhibitors, and the response has been tremendous. MiT's MovEsports System for SNDBX is a perfect fit for exhibitors interested in easily entering the Esports community. We are thrilled to deliver MovEsports systems for SNDBX to the first SNDBX leagues." Rick Starr, CEO of SNDBX stated: "We are excited that cinmas will be hosting amateur Esports leagues on the big screen. There has been a massive movement by exhibitors into alternative uses for their auditoriums. Cinemas partnering with SNDBX will allow us to scale these local leagues across North America."

07:08 EST Scotts Miracle-Gro says Project Springboard to exceed $185M annualized savings - Both phases of Project Springboard are now expected to deliver $185 million of annualized savings in fiscal 2023 ahead of schedule with line of sight to additional savings through fiscal 2024, reflecting the high level of financial discipline company-wide and partially mitigating higher interest expense and volume loss at Hawthorne this year.

07:06 EST Old Dominion boosts dividend 33.3% to 40c - The Company's Board of Directors has declared a first-quarter dividend of 40c per share, payable on March 15, , to shareholders of record at the close of business on March 1. This dividend represents a 33.3% increase to the quarterly cash dividend paid in the first quarter of 2022. Mr. Gantt concluded, "Old Dominion's record-breaking results in 2022 reflect the strength of our team and their unwavering commitment to provide our customers with superior service. While we have recently announced the transition to our next President and Chief Executive Officer, I can proudly assure you that our entire team will remain fully committed to executing the same strategic plan that has helped us produce profitable growth over the long term. There will be no change in our commitment to service nor will we change our approach of investing in our service center network, our technology and, most importantly, our OD Family of employees. With our ongoing and steadfast commitment to the core principles that have differentiated us in the marketplace, we are confident that we can continue to win market share and increase shareholder value."

07:05 EST Old Dominion:Q4 operating ratio up 240 basis points to 71.2% vs. last year - "The operating ratio for the fourth quarter improved 240 basis points to 71.2% as compared to the fourth quarter of 2021. We continued to operate efficiently during the quarter, despite the decline in volumes, and we also continued our diligent approach to managing our discretionary spending. Our salaries, wages and benefit costs as a percent of revenue improved to 44.0% from 46.9% in the fourth quarter of 2021, and our purchased transportation costs decreased 200 basis points to 1.9% of revenue. The combination of these improvements more than offset the increase in operating supplies and expenses as a percent of revenue that primarily resulted from the significant increase in the cost of diesel fuel and other petroleum-based products during the quarter."

07:04 EST KKR announces significant investment in Groundworks - Groundworks, a foundation repair and water management services company, and KKR announced a significant investment in Groundworks as part of a new strategic partnership with KKR. Cortec Group, Groundworks' current growth partner, will remain an important shareholder in the Company and member of the board of directors. Founded in 2016, Groundworks has more than 4,000 employees operating in 33 states providing residential foundation and water management solutions, including foundation repair, basement waterproofing, crawl space repair and encapsulation, plumbing, gutter installation, and concrete lifting services. As part of this transaction, Groundworks will expand its equity ownership program to make all employees owners of the Company. This strategy is based on the belief that employee engagement is a key driver in building stronger companies. KKR is making the investment primarily through its North America XIII Fund. The transaction, which is subject to receipt of required regulatory approvals and satisfying other customary closing conditions, is expected to close in the Q1. Harris Williams served as exclusive financial advisor and Paul Hastings served as legal counsel to Groundworks. Deutsche Bank Securities and William Blair & Company, served as buyside financial advisors and Simpson Thacher & Bartlett served as legal counsel to KKR.

07:02 EST Veeco acquires Epiluvac to penetrate into high growth SiC equipment market - Veeco Instruments announced that on January 31, 2023, it acquired Epiluvac AB, a privately held manufacturer of chemical vapor deposition epitaxy systems that enable advanced silicon carbide, SiC, applications in the electric vehicle market. Epiluvac, based in Sweden, was founded in 2013 by a highly experienced team in SiC. Epiluvac's technology platform combined with Veeco's global go-to-market capabilities create a significant long-term growth driver for Veeco. "The Epiluvac team has developed a superior platform and process know-how aligned with markets that are a great strategic fit for Veeco," said Bill Miller, Veeco's Chief Executive Officer. "Their well-designed CVD platform achieves high productivity, is easy to maintain and has superior process control capability that make it uniquely qualified to produce devices that enable lighter, smaller and more efficient power conversion systems. We see this acquisition as a great complement to our metal organic chemical vapor deposition epitaxy product line. This acquisition accelerates our penetration into the emerging, high-growth SiC equipment market by reducing our time to market."

06:57 EST Computer Task Group achieves AWS Service Delivery designation - CTG (CTG) announced it has achieved the Amazon (AMZN) Web Services, or AWS, Service Delivery designation for Amazon Connect. Achieving the AWS Service Delivery designation for Amazon Connect, a cloud-based contact center service, differentiates CTG as an AWS Partner Network, or APN, member that provides specialized technical proficiency, proven customer experience, and success in delivering Amazon Connect. To receive the designation, APN partners must possess deep experience and the capabilities to deliver solutions seamlessly on AWS. CTG was required to pass a rigorous evaluation to ensure Amazon Connect best practices were being followed.

06:48 EST Roche reports EC approves label expansion of Hemlibra - Roche announced that the European Commission approved the expansion of the Hemlibra European Union marketing authorization. The label will now include the routine prophylaxis of bleeding episodes in people with hemophilia A without factor VIII inhibitors, who have moderate disease with a severe bleeding phenotype. "We welcome the European Commission's decision to approve Hemlibra also for people with moderate hemophilia A in the EU, since even moderate disease can produce bleeds that cause irreversible joint damage and impact quality of life," said Levi Garraway, M.D., Ph.D., Roche's Chief Medical Officer and Head of Global Product Development.

06:46 EST GSK reports Benlysta granted orphan drug designation by FDA - GSK plc announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to Benlysta, a B-cell inhibiting monoclonal antibody, for the potential treatment of systemic sclerosis. GSK plans to initiate a phase II/III trial of belimumab for systemic sclerosis associated interstitial lung disease, or SSc-ILD, in the first half of 2023.

06:43 EST Humana appoints Sanjay Shetty to lead health care services business - Humana has hired health care industry veteran Sanjay Shetty, M.D., MBA, to lead its health care services business, CenterWell, the largest provider of senior-focused primary care, the largest provider of home health services, and fourth largest pharmacy benefit manager in the U.S. Shetty comes to Humana from Steward Health Care System where he currently serves as President. In his new role, he will report to Humana President and CEO Bruce Broussard and will serve as a member of Humana's Management Team starting April 1.

06:36 EST Ingersoll-Rand acquires Paragon Tank Truck Equipment for $40M - Ingersoll Rand has acquired Paragon Tank Truck Equipment for an all-cash purchase price of approximately $40M. Paragon is a leading provider of solutions used for loading and unloading dry bulk and liquid tanks on and off of trucks. Its solutions include pneumatic blowers, stationary packages and accessories for dry bulk and hydraulic packages, coolers, air compressors and accessories for the liquid segment. Paragon is headquartered in Cartersville, GA, has approximately 55 employees and annual revenue of more than $25M. It will join the Industrial Technologies and Services, or ITS, segment of Ingersoll Rand.

06:15 EST Dorian LPG declares irregular cash dividend of $1.00 per share - Dorian LPG announced that its board of directors has declared an irregular cash dividend of $1.00 per share of the company's common stock, returning over $40.3M of capital to shareholders. The dividend is payable on or about February 28 to all shareholders of record as of the close of business on February 15.

06:06 EST Brunswick reports strong start to the 2023 boat show season - Brunswick and its brands have reported a strong start to the 2023 boat show season, highlighting the Company's continued market momentum and showcasing of its ACES Innovation strategy. Brunswick kicked off 2023 with a very successful Consumer Electronics Show, or CES, in Las Vegas where the Company highlighted its ACES Innovation Strategy with the launch of multiple new products including its newest boat brand, Veer and Mercury's first Avator electric engine.

05:25 EST Atlas Air takes delivery of final 747 to be produced by Boeing - Atlas Air (AAWW) announced it has taken delivery of the final 747 ever to be produced by Boeing (BA). The delivery of this aircraft is the last of four new Boeing 747-8 Freighters Atlas ordered in January 2021. Atlas Air will operate this aircraft for Apex Logistics, a Kuehne+Nagel company, under a long-term agreement.

05:18 EST Xos receives order for 150 armored EVs from Loomis - Loomis has signed an agreement with Xos for the delivery of 150 armored electric vehicles, or EVs, for the U.S. market. By the end of 2022, Loomis had 20 armored EVs in the U.S. from the same supplier, that met the requirements in terms of safety, range and weight.

05:14 EST Rio Tinto announces recovery of radioactive capsule in Australia - The company said, "Rio Tinto expresses its gratitude to the Western Australia's Department of Fire and Emergency Services for coordinating the successful search effort to locate a missing capsule lost while in transit from the company's Gudai-Darri iron ore mine in the Pilbara, Western Australia. Rio Tinto would also like to thank the specialist search crews from the Australian Defence Force, the Australian Radiation Protection and Nuclear Safety Agency and the Australian Nuclear Science and Technology Organisation, as well as all other support agencies, for their crucial role in the search and recovery efforts."

05:08 EST XPeng delivers 5,218 Smart EVs in January - XPeng announced its vehicle delivery results for January. XPeng delivered 5,218 Smart EVs in January. January deliveries included 2,249 G9 SUVs. Vehicle deliveries for the month reflected seasonal slowdown during the Chinese New Year holiday period which began in mid-January. The company will soon unveil the new version of the P7 smart sedan.